No Prescription |
 |
 | ||
|
Alerid Zyrtec |
|
| ||
No Prescription » Prescription Drugs 1 » Alerid Zyrtec Cetirizine is an antihistamine. It is prescribed to treat the sneezing; itchy runny nose; and itchy red watery eyes caused by seasonal allergies such as hay fever. Cetirizine also relieves the symptoms of year-round allergies due to dust mold and animal dander. Preventing or treating symptoms of hay fever and other upper respiratory allergies such as stuffy nose runny nose sneezing itching of the nose and throat and itchy watery eyes. It is also used for preventing or treating chronic hives. Cetirizine is an antihistamine. It works by blocking the action of histamine and reduces the symptoms of an allergic reaction. Buy Alerid Zyrtec and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Alerid Zyrtec: Product Type: Prescription Drugs 1 Alerid (Zyrtec Generic Cetirizine) Alerid (Zyrtec Generic Cetirizine) Zyrtec Generic Cetirizine 10mg 400(4 x 100) Tablets 100 Tablets 200(2 x 100) Tablets Zyrtec Generic Cetirizine Alerid
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
